Skip to main content
. Author manuscript; available in PMC: 2019 Mar 10.
Published in final edited form as: J Control Release. 2018 Feb 2;273:147–159. doi: 10.1016/j.jconrel.2018.01.027

Figure 6.

Figure 6

(A, B) Total IgG, (C, D) IgG1, and (E, F) IgG2b anti-ovalbumin (OVA) antibodies in mouse sera collected on Day 14, 28, and 42 post vaccination with OVA microparticles (MPs), soluble monophosphoryl lipid A (MPL), soluble OVA (solOVA), Alhydrogel (alum), empty MPs (EMPs), or PBS. (B, D, F) Antibody levels for OVA MPs + MPL treatment were plotted against MP cyclic acetal coverage (CAC) with best-fitted functions as a visual guide. Data are displayed as (A, C, E) the mean logarithmic transformation (base 10) of the titers (ng/mL) ± standard error of the mean or (D, E, F) mean ± standard error of the mean (n = 8 except for Day 42 where n=4). Statistical significance between the groups of interest (OVA MPs + MPL) at various time points is presented as *p < 0.05 and **p < 0.01.